PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy

Acta Biomaterialia

Volumn 39, Issue , 2016, Pages 94-105

  Choi, Ju Yeon ^a   Ramasamy, Thiruganesh ^a   Kim, Sung Yub ^a   Kim, Jeonghwan ^a   Ku, Sae Kwang ^b   Youn, Yu Seok ^c   Kim, Jae Ryong ^d   Jeong, Jee Heon ^a   Choi, Han Gon ^e   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Daegu Haany University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Hanyang University   (South Korea)

Author keywords

Axitinib; Celastrol; Lipid; Mesoporous silica nanoparticle; Mitochondria

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; ENDOTHELIAL CELLS; LIPID BILAYERS; LIPOSOMES; MESOPOROUS MATERIALS; MITOCHONDRIA; TARGETED DRUG DELIVERY; TUMORS;

ANGIOGENESIS; ANTICANCER EFFECTS; AXITINIB; BI-LAYER; CELASTROLS; DRUG COMBINATIONS; MESOPOROUS SILICA NANOPARTICLES; MITOCHONDRIAL FUNCTION; MITOCHONDRIAS; TUMOR INHIBITION;

CELL DEATH;

AXITINIB; CASPASE 3; CD31 ANTIGEN; CELASTROL; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MESOPOROUS SILICA NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; LIPID BILAYER; NANOPARTICLE; SILICON DIOXIDE; TRIPTERINE; TRITERPENE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID BILAYER; MITOCHONDRION; MOUSE; NONHUMAN; PEGYLATED LIPID BILAYER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEMALE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PHARMACOKINETICS; PHARMACOLOGY; POROSITY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; IMIDAZOLES; INDAZOLES; LIPID BILAYERS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POROSITY; SILICON DIOXIDE; TRITERPENES;

EID: 84966705255     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.05.012     Document Type: Article

References (45)

1. [1] He, M., Rosen, J., Mangiameli, D., Libutti, S.K., Cancer development and progression. Adv. Exp. Med. Biol. 593 (2013), 117–133.
2. [2] Ghobrial, I.M., Witzig, T.E., Adjei, A.A., Targeting apoptosis pathways in cancer therapy. Cancer J. Clin. 55 (2005), 178–194.
3. [3] Desai, B.N., Myers, B.R., Schreiber, S.L., FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Natl. Acad. Sci. 99 (2002), 4319–4324.
4. [4] Boland, M.L., Chourasia, A.H., Macleod, K.F., Mitochondrial dysfunction in cancer. Front. Oncol., 3, 2013, 292.
5. [5] Matsumoto, T., Claesson-Welsh, L., VEGF receptor signal transduction. Sci. STKE, 2001, RE21.
6. [6] Masuko, U.F., Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc. Res. 71 (2006), 226–235.
7. [7] Brunelle, J.K., Bell, E.J., Quesada, N.M., Vercauteren, K., Tiranti, V., Zeviani, M., Scarpulla, R.C., Chandel, N.S., Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1 (2005), 409–414.
8. [8] Mansfield, K.D., Guzy, R.D., Pan, Y., Young, R.M., Cash, T.P., Schumacker, P.T., Simon, M.C., Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular sensing and hypoxic HIF-alpha activation. Cell Metab. 1 (2005), 393–399.
9. [9] Huang, L., Zhang, Z., Zhang, S., Ren, J., Zhang, R., Zeng, H., Li, Q., Wu, G., Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway. Int. J. Mol. Med. 27 (2011), 407–415.
10. [10] Han, X., Sun, S., Zhao, M., Cheng, X., Chen, G., Lin, S., Guan, Y., Yu, X., Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1a protein synthesis. PLoS ONE, 9, 2014, e112470.
11. [11] Pemovska, T., Johnson, E., Kontro, M., Repasky, G.A., Chen, J., Wells, P., Cronin, C.N., McTigue, M., Kallioniemi, O., Porkka, K., Murray, B.W., Wennerberg, K., Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519 (2015), 102–105.
12. [12] Escudier, B., Gore, M., Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 11 (2011), 113–126.
13. [13] Ma, J., Han, L.Z., Liang, H., Mi, C., Shi, H., Lee, J.J., Jin, X., Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. Oncol. Rep. 32 (2014), 235–242.
14. [14] Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., Aggarwal, B.B., Liu, M., Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70 (2010), 1951–1959.
15. [15] Sethi, G., Ahn, K.S., Pandey, M.K., Aggarwal, B.B., Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109 (2007), 2727–2735.
16. [16] Ramasamy, T., Tran, T.H., Cho, H.J., Kim, J.H., Kim, Y.I., Jeon, J.Y., Choi, H.G., Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm. Res. 31 (2014), 1302–1314.
17. [17] Ramasamy, T., Haidar, Z.S., Tran, T.H., Choi, J.Y., Jeong, J.H., Shin, B.S., Choi, H.G., Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 10 (2015), 5116–5127.
18. [18] Ramasamy, T., Ruttala, H.B., Choi, J.Y., Tran, T.H., Kim, J.H., Ku, S.K., Choi, H.G., Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan. Chem. Commun. 51 (2015), 5758–5761.
19. [19] Ramasamy, T., Choi, J.Y., Cho, H.J., Umadevi, S.K., Shin, B.S., Choi, H.G., Yong, C.S., Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization. Pharm. Res. 32 (2015), 1947–1956.
20. [20] Choi, J.Y., Ramasamy, T., Tran, H.T., Ku, S.K., Shin, B.S., Choi, H.G., Yong, C.S., Kim, J.O., Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth. J. Mater. Chem. B 3 (2015), 408–416.
21. [21] Yang, P., Gai, S., Lin, J., Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 41 (2012), 3679–3698.
22. [22] Argyo, C., Weiss, V., Bräuchle, C., Thomas, B., Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery.Chem. Mater.., 26, 2013, 435–451.
23. [23] Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006), 621–681.
24. [24] Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446.
25. [25] Ramsay, E.C., Dos Santos, N., Dragowska, W.H., Laskin, J.J., Bally, M.B., The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr. Drug Deliv. 2 (2005), 341–351.
26. [26] Lee, J.H., Nan, A., Combination drug delivery approaches in metastatic breast cancer. J. Drug Delivery, 2012, 2012, 915375.
27. [27] Mudakavi, R.J., Raichur, A.M., Chakravortty, D., Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections. RSC Adv. 4 (2014), 61160–61166.
28. [28] Bittmanand, R., Blau, L., The phospholipid-cholesterol interaction. Kinetics of water permeability in liposomes. Biochemistry 11 (1972), 4831–4839.
29. [29] Ruttala, H.B., Ko, Y.T., Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy. Pharm. Res. 32 (2014), 1002–1016.
30. [30] Ramasamy, T., Kim, J.H., Choi, H.G., Yong, C.S., Kim, J.O., Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J. Biomed. Nanotechnol. 10 (2014), 1304–1312.
31. [31] Zheng, M., Yue, C., Ma, Y., Gong, P., Zhao, P., Zheng, C., Sheng, Z., Zhang, P., Wang, Z., Cai, L., Single-step assembly of DOX/ICG loaded lipid–polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 7 (2013), 2056–2057.
32. [32] Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000), 271–284.
33. [33] Nogueira, D.R., Tavano, L., Mitjans, M., Pérez, L., Infante, M.R., Vinardell, M.P., In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials 34 (2013), 2758–2772.
34. [34] Li, Y., Kroger, M., Liu, W.K., Endocytosis of PEGylated nanoparticles accompanied by structural and free energy changes of the grafted polyethylene glycol. Biomaterials 35 (2014), 8467–8478.
35. [35] Ramasamy, T., Tran, T.H., Choi, J.Y., Cho, H.J., Kim, J.H., Yong, C.S., Choi, H.G., Kim, J.O., Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr. Polym. 104 (2014), 653–661.
36. [36] Morales, A., Colell, A., García-Ruiz, C., Fernández-Checa, J.C., Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 11 (2009), 2685–2700.
37. [37] Powis, G., Kirkpatrick, L., Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther. 3 (2004), 647–654.
38. [38] Wei, M.C., Zong, W.X., Cheng, E.H., Indsten, L.T., Panoutsakopoulou, V., Ross, A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., Korsmeyer, S.J., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001), 727–730.
39. [39] Narita, M., Shimizu, S., Ito, T., Chittenden, T., Lutz, R.J., Matsuda, H., Tsujimoto, Y., Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 14681–14686.
40. [40] Marzo, I., Brenner, C., Zamzami, N., Jürgensmeier, J.M., Susin, S.A., Vieira, H.L., Prévost C, M., Xie, Z., Atsuyama, M.S., Reed, J.C., Kroemer, G., Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281 (1998), 2027–2031.
41. [41] Mendoza, A.E.H., Préat, V., Mollinedo, F., Blanco-Prieto, M.J., In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Controlled Release 156 (2011), 421–426.
42. [42] Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003), 721–732.
43. [43] Ramasamy, T., Kim, J.H., Choi, J.Y., Tran, T.H., Choi, H.G., Yong, C.S., Kim, J.O., PH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy. J. Mater. Chem. B 2 (2014), 6324–6333.
44. [44] Chambers, A.F., Groom, A.C., MacDonald, I.C., Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2 (2002), 563–572.
45. [45] Folkman, J., What is the evidence that tumors are angiogenesis dependent?. J. Natl Cancer Inst. 82 (1990), 4–6.